6-isopropyl-7,8-dihydro-6H-[1,6]naphthyridin-5-one | 1312751-60-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-isopropyl-7,8-dihydro-6H-[1,6]naphthyridin-5-one
• 英文别名: 6-Propan-2-yl-7,8-dihydro-1,6-naphthyridin-5-one；6-propan-2-yl-7,8-dihydro-1,6-naphthyridin-5-one
• CAS: 1312751-60-2
• 化学式: C₁₁H₁₄N₂O
• 分子量: 190.245
• InChiKey: HRLZMLXQVPNUEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  33.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-isopropyl-7,8-dihydro-6H-[1,6]naphthyridin-5-one 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 copper(l) iodide 、 三乙胺 、 间氯过氧苯甲酸 、 三氯氧磷 作用下， 以 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.33h， 生成 6-isopropyl-2-trimethylsilanylethynyl-7,8-dihydro-6H-[1,6]naphthyridin-5-one
  参考文献：
  名称：

  Efficacy switching SAR of mGluR5 allosteric modulators: Highly potent positive and negative modulators from one chemotype

  摘要：

  A series of metabotropic glutamate 5 receptor (mGluR5) allosteric ligands with positive, negative or no modulatory efficacy is described. The ability of this series to yield both mGluR5 PAMs and NAMs with single-digit nanomolar potency is unusual, and the underlying SAR is detailed. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.03.103
• 作为产物：
  描述：

  2-氯烟酸乙酯 在 bis-triphenylphosphine-palladium(II) chloride 、 2,6-二叔丁基-4-甲基苯酚 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 6-isopropyl-7,8-dihydro-6H-[1,6]naphthyridin-5-one
  参考文献：
  名称：

  Efficacy switching SAR of mGluR5 allosteric modulators: Highly potent positive and negative modulators from one chemotype

  摘要：

  A series of metabotropic glutamate 5 receptor (mGluR5) allosteric ligands with positive, negative or no modulatory efficacy is described. The ability of this series to yield both mGluR5 PAMs and NAMs with single-digit nanomolar potency is unusual, and the underlying SAR is detailed. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.03.103

文献信息

• Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US11186564B2

  公开（公告）日：2021-11-30

  Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

  式 I 的化合物： 以及含有此类化合物的药物组合物。还公开了治疗有需要的患者的神经或精神障碍的方法。此类疾病包括抑郁症、双相情感障碍、疼痛、精神分裂症、强迫症、成瘾症、社交障碍、注意力缺陷多动障碍、焦虑症、自闭症、认知障碍或神经精神症状，如冷漠、抑郁、焦虑、精神病、攻击性、激动、冲动控制障碍，以及神经系统疾病如阿尔茨海默病和帕金森病的睡眠障碍。
• Efficacy switching SAR of mGluR5 allosteric modulators: Highly potent positive and negative modulators from one chemotype
  作者：Anette Graven Sams、Gitte Kobberøe Mikkelsen、Robbin M. Brodbeck、Xiaosui Pu、Andreas Ritzén

  DOI：10.1016/j.bmcl.2011.03.103

  日期：2011.6

  A series of metabotropic glutamate 5 receptor (mGluR5) allosteric ligands with positive, negative or no modulatory efficacy is described. The ability of this series to yield both mGluR5 PAMs and NAMs with single-digit nanomolar potency is unusual, and the underlying SAR is detailed. (C) 2011 Elsevier Ltd. All rights reserved.